2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2287

Altered Regulation of Metabolic Pathways in Systemic Sclerosis Evidenced by Metabolomics
Abstract Number: 674

Altered Response to B Cell Receptor (BCR) Crosslinking in SLE: Correlation with Genetic Risk Variants Predicted to Impact BCR Signaling
Abstract Number: 2115

Altered Serum Levels of Bone Metabolism Markers in Rheumatoid Arthritis
Abstract Number: 645

Altered Soluble Inflammatory Mediators Mark Impending Systemic Lupus Erythematosus Disease Flare in European-American Lupus Patients Who Receive Influenza Vaccination
Abstract Number: 673

Altered Soluble Mediators in Individuals with Incomplete Lupus (ILE) in the Lupus Autoimmunity in Relatives (LAUREL) Study
Abstract Number: 856

Am80, a Retinoic Acid Receptor Agonist, Ameliorates Murine Vasculitisthrough the Suppression of Neutrophil Migration and Activation
Abstract Number: 1745

Amelioration of Experimental Autoimmune Arthritis by Adoptive Transfer of Foxp3-Expressing Regulatory B Cells Is Associated with the Regulatory T Cell/T helper 17 cell Balance
Abstract Number: 210

An Analysis of Metabolic Syndrome in Adult Dermatomyositis with a Focus On Cardiovascular Disease
Abstract Number: 768

An Easy to Use Referral Model for Arthritis From the Rotterdam Early Arthitis Cohort
Abstract Number: 483

An Evaluation of Literature On Discontinuation Rates of Biologics in Rheumatoid Arthritis
Abstract Number: 2131

An Evaluation of Prognostic Factors for Orthopaedic Joint Surgery in Rheumatoid Arthritis. Results From Two Multicentre UK Inception Cohorts (1986-2011)
Abstract Number: 851

An Evidence-Based Screening Algorithm for Pulmonary Arterial Hypertension in Systemic Sclerosis
Abstract Number: 2659

An Expanded Repertoire of Anti-Citrullinated Peptide Antibodies Is Associated with Interstitial Lung Disease in Rheumatoid Arthritis
Abstract Number: 1296

An Interim Analysis of the Efficacy of Abatacept in Japanese Biologics-naïve Rheumatoid Arthritis Patients (results from ABROAD study): Comparison of CRP and MMP-3 Level After Treatment with Abatacept Versus Anti-TNF Agents
Abstract Number: 2401

An International Framework for Chronic Condition Self Management Support: Results from an International Electronic Consultation Process.

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].